A Polymorphism (rs2295080) in mTOR Promoter Region and Its Association with Gastric Cancer in a Chinese Population

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Xu, Ming ^a,b   Tao, Guoquan ^c   Kang, Meiyun ^a,b   Gao, Yan ^a,b   Zhu, Haixia ^a,d   Gong, Weida ^e   Wang, Meilin ^a,b   Wu, Dongmei ^a,b   Zhang, Zhengdong ^a,b   Zhao, Qinghong ^f  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Nanjing Medical University   (China)

^c THE AFFILIATED HUAIAN NO 1 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d NANTONG TUMOR HOSPITAL   (China)

^e Yixing Cancer Hospital   (China)

^f THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA;

AGED; ARTICLE; BINDING AFFINITY; CANCER RISK; CHINESE; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MTOR GENE; POPULATION RESEARCH; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH ADENOCARCINOMA; STOMACH CANCER;

AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 84875525196     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060080     Document Type: Article

References (35)

1. Ferlay J SH, Bray F, Forman D,Mathers C, Parkin DM (2010) GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer, 2010. Available at: http://globocan.iarc.fr. 2008.
2. Menges M, Hoehler T, (2009) Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction. J Cancer Res Clin Oncol 135: 29-38.
3. Dancey JE, (2006) Therapeutic targets: mTOR and related pathways. Cancer Biol Ther 5: 1065-1073.
4. Hudes GR, (2009) Targeting mTOR in renal cell carcinoma. Cancer 115: 2313-2320.
5. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, et al. (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24: 200-216.
6. Edinger AL, Thompson CB, (2002) Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 13: 2276-2288.
7. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ, (2006) Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 12: 7215-7220.
8. Wysocki PJ, (2009) mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev Mol Diagn 9: 231-241.
9. Smrz D, Kim MS, Zhang S, Mock BA, Smrzova S, et al. (2011) mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood 118: 6803-6813.
10. Yang Q, Guan KL, (2007) Expanding mTOR signaling. Cell Res 17: 666-681.
11. Sarbassov DD, Ali SM, Sabatini DM, (2005) Growing roles for the mTOR pathway. Curr Opin Cell Biol 17: 596-603.
12. Al-Batran SE, Ducreux M, Ohtsu A, (2012) mTOR as a therapeutic target in patients with gastric cancer. Int J Cancer 130: 491-496.
13. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, et al. (2009) Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 27: 857-871.
14. Pu X, Hildebrandt MA, Lu C, Lin J, Stewart DJ, et al. (2011) PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer 71: 82-88.
15. Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, et al. (2009) Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis 30: 2047-2052.
16. Slattery ML, Herrick JS, Lundgreen A, Fitzpatrick FA, Curtin K, et al. (2010) Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Carcinogenesis 31: 1604-1611.
17. Huang L, Huang J, Wu P, Li Q, Rong L, et al. (2011) Association of genetic variations in mTOR with risk of childhood acute lymphoblastic leukemia in a Chinese population. Leuk Lymphoma. Leuk Lymphoma 2012 53: 947-951.
18. Wang M, Bai J, Tan Y, Wang S, Tian Y, et al. (2011) Genetic variant in PSCA predicts survival of diffuse-type gastric cancer in a Chinese population. Int J Cancer 129: 1207-1213.
19. Green FL PD, Fleming ID, Fritz AG, Balch CM, Haller, DG ea AJCC cancer staging manual. 6th ed. New York:Springer Press; 2002. p. 111-118.
20. Sanghera KP, Mathalone N, Baigi R, Panov E, Wang D, et al. (2011) The PI3K/Akt/mTOR pathway mediates retinal progenitor cell survival under hypoxic and superoxide stress. Mol Cell Neurosci 47: 145-153.
21. Yu J, Yaba A, Kasiman C, Thomson T, Johnson J, (2011) mTOR controls ovarian follicle growth by regulating granulosa cell proliferation. PLoS One 6: e21415.
22. Li J, Liu J, Song J, Wang X, Weiss HL, et al. (2011) mTORC1 inhibition increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. Am J Physiol Cell Physiol 301: C213-226.
23. Kudo M, (2011) mTOR inhibitor for the treatment of hepatocellular carcinoma. Dig Dis 29: 310-315.
24. Le Tourneau C, Faivre S, Serova M, Raymond E, (2008) mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 99: 1197-1203.
25. Schatz JH, (2011) Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies. Curr Oncol Rep 13: 398-406.
26. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, et al. (2009) Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 18: 1333-1349.
27. Marinov M, Fischer B, Arcaro A, (2007) Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol 63: 172-182.
28. Schiewer MJ, Den R, Hoang DT, Augello MA, Lawrence YR, et al. (2012) mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocr Relat Cancer 19: 1-12.
29. Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, et al. (2007) The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 85: 54-60.
30. Chen J, Shao P, Cao Q, Li P, Li J, et al. (2012) Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population. PLoS One 7: e40817.
31. Huang L, Huang J, Wu P, Li Q, Rong L, et al. (2012) Association of genetic variations in mTOR with risk of childhood acute lymphoblastic leukemia in a Chinese population. Leuk Lymphoma 53: 947-951.
32. Cao Q, Ju X, Li P, Meng X, Shao P, et al. (2012) A functional variant in the mTOR promoter modulates its expression and is associated with renal cell cancer risk. PLoS One 7: e50302.
33. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ, (2009) Gastric cancer. Lancet 374: 477-490.
34. Galoian KA, Temple TH, Galoyan A, (2011) Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA 231 (ER-) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors. Tumour Biol 32: 745-751.
35. Fang Z, Zhang T, Dizeyi N, Chen S, Wang H, et al. (2012) Androgen receptor enhances p27 degradation in prostate cancer cells through rapid and selective TORC2 activation. J Biol Chem 287: 2090-2098.